三生制药获辉瑞“重金”押注。5月20日,三生制药公告,公司及两家附属公司沈阳三生制药有限责任公司(简称沈阳三生)、三生国健与跨国药企辉瑞就PD-1/VEGF双特异性抗体SSGJ-707达成全球授权协议。根据协议,辉瑞将支付12.5亿美元(90亿元)的首付款、最高可达48亿美元里程碑付款,以及根据授权地区产品销售额计算得到的两位数百分比的梯度销售分成。此次交易的潜在总金额高达60.5亿美元,约合...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.